The state of Texas has participated in settlement agreements with different companies to resolve legal claims against them for their role in the opioid crisis. The companies include opioid marketing consultant McKinsey, pharmaceutical companies Endo and Teva, opioid manufacturer Johnson & Johnson ("Janssen") and pharmaceutical distributors AmerisourceBergen, Cardinal Health and McKesson. The amount of funding Texas anticipates receiving is dependent on the number of local governments that join the settlement agreements.
As of early 2023, some opioid related litigation is ongoing. The Office of the Attorney General is working with political subdivisions to sign on to additional settlement proceedings. For information regarding ongoing opioid litigation, contact the Office of the Attorney General.
Of the total amounts received from statewide opioid settlement agreements, 15 percent is deposited to the Opioid Abatement Account and 85 percent is deposited to the Opioid Abatement Trust Fund (Trust Fund) held at the Texas Treasury Safekeeping Trust Company (TTSTC). The Trust Fund is held at the TTSTC outside of the state treasury.
The Opioid Abatement Account is an account in general revenue consisting primarily of amounts from statewide opioid settlement agreements. Funds in the account may be appropriated through the legislative process only to a state agency to address opioid-related prevention, treatment programs and as otherwise permitted by statute or appropriation.
Of the total settlement amounts: